Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme Provides Update On Allston Landing Plant
FDA has informed Genzyme that it will re-inspect the company’s Allston Landing manufacturing facility. The re-inspection is a follow-up to an inspection the agency conducted in May 2009,
FDA has informed Genzyme that it will re-inspect the company’s Allston Landing manufacturing facility. The re-inspection is a follow-up to an inspection the agency conducted in May 2009,
Arkema and Dow have entered into an agreement for Dow to meet FTC required divestitures, related to its acquisition of Rohm and Haas Company. Arkema will buy a
Graceway has provided the results from a phase III program evaluating short-course regimens of two concentrations of imiquimod cream (3.75% and 2.5%). The data demonstrated imiquimod 3.75%, administered
Germany-based Merck has set new climate protection targets for its global pharmaceutical and chemical operations: by the year 2020, global carbon dioxide emissions are to be reduced by
The Addario Lung Cancer Medical Institute (ALCMI) has signed a letter of intent (LOI) collaboration agreement with Response Genetics (RGI), on molecular diagnostic testing and banking of advanced-stage
Oculus Innovative Sciences has announced the closing of an offering to sell securities to selected investors, for aggregate gross proceeds of approximately $6 million. The offering was made
ImmunoGen has provided the initial efficacy, safety and tolerability clinical data of IMGN901, for the treatment of small-cell lung cancer (SCLC). IMGN901 is in early clinical testing and
FDA has approved Invega Sustenna (paliperidone palmitate) extended-release injectable suspension for maintenance and treatment of schizophrenia in adults. The approval is based on four acute symptom control studies
Pharmasset has reported positive preliminary results from phase I clinical trial of PSI-7851, for the treatment of hepatitis C (HCV). PSI-7851 is a second generation nucleotide polymerase inhibitor
BioMarin has posted GAAP net income of $1.3m ($0.01 per diluted share) for the second quarter of 2009, compared to GAAP net income of $3.8m ($0.04 per diluted